MCID: PRS021
MIFTS: 49

Prostatic Adenoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Prostatic Adenoma

MalaCards integrated aliases for Prostatic Adenoma:

Name: Prostatic Adenoma 12 55 15 73
Prostatic Hyperplasia 44 73
Benign Prostatic Hyperplasia 73
Benign Adenoma of Prostate 12
Adenoma of Prostate 12
Adenoma - Prostate 12
Prostate Adenoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2883
MeSH 44 D011470
NCIt 50 C4795
SNOMED-CT 68 21173002

Summaries for Prostatic Adenoma

Disease Ontology : 12 An adenoma that is located in the prostate.

MalaCards based summary : Prostatic Adenoma, also known as prostatic hyperplasia, is related to prostate disease and impotence, and has symptoms including prostatism An important gene associated with Prostatic Adenoma is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Calcium signaling pathway and Necroptosis. The drugs UroXatral and Leuprolide have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and bone.

Related Diseases for Prostatic Adenoma

Diseases related to Prostatic Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Related Disease Score Top Affiliating Genes
1 prostate disease 32.0 KLK3 SRD5A1
2 impotence 30.6 KLK3 SRD5A1
3 prostatic hyperplasia, benign 29.5 KLK3 SRD5A1
4 prostate cancer 11.7
5 prostatic hypertrophy 11.5
6 adenoma 10.6
7 prostatitis 10.5
8 adenocarcinoma 10.4
9 hermansky-pudlak syndrome 10.3
10 aging 10.3
11 suppression of tumorigenicity 12 10.2
12 alopecia 10.2
13 insulin-like growth factor i 10.1
14 androgenic alopecia 10.1
15 alopecia, androgenetic, 1 10.1
16 sexual disorder 10.1
17 bladder cancer 10.0
18 body mass index quantitative trait locus 1 10.0
19 liver disease 10.0
20 urethral stricture 10.0
21 fatty liver disease 10.0
22 depression 10.0
23 varicocele 10.0
24 cystitis 10.0
25 hyperinsulinism 10.0
26 acromegaly 10.0
27 ischemia 10.0
28 urinary tract obstruction 9.9
29 hypertension, essential 9.9
30 vesicoureteral reflux 1 9.9
31 mitochondrial import-stimulating factor 9.9
32 pulmonary disease, chronic obstructive 9.9
33 chronic kidney failure 9.9
34 diabetes mellitus 9.9
35 leukemia 9.9
36 lymphoma 9.9
37 neurogenic bladder 9.9
38 dementia 9.9
39 acute cystitis 9.9
40 interstitial cystitis 9.9
41 hypogonadism 9.9
42 kidney disease 9.9
43 hypogonadotropism 9.9
44 degos 'en cocarde' erythrokeratoderma 9.8
45 alzheimer disease 9.7
46 breast cancer 9.7
47 ovarian cancer 9.7
48 neutrophil actin dysfunction 9.7
49 retinitis pigmentosa 9.7
50 urinary tract infections, recurrent 9.7

Graphical network of the top 20 diseases related to Prostatic Adenoma:



Diseases related to Prostatic Adenoma

Symptoms & Phenotypes for Prostatic Adenoma

UMLS symptoms related to Prostatic Adenoma:


prostatism

Drugs & Therapeutics for Prostatic Adenoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
UroXatral 18 ALFUZOSIN HYDROCHLORIDE Sanofi-aventis June 2003

Drugs for Prostatic Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 8)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
2
Etidronic acid Approved Phase 3 7414-83-7, 2809-21-4 3305
3 Androgens Phase 3
4 Calcium, Dietary Phase 3
5 Risedronate Sodium Phase 3 115436-72-1
6 Bone Density Conservation Agents Phase 3
7 calcium channel blockers Phase 3
8 Anesthetics Not Applicable

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) Completed NCT01494337 Phase 4
2 Evaluation of the Effects of Different Prostate Surgeries on Urinary and Sexual Function Completed NCT01810068 Phase 4
3 GreenLight Laser Photoselective Vaporization of the Prostate vs Plasma Kinetic Vaporization of the Prostate; RCT Active, not recruiting NCT02283684 Phase 4
4 Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer Completed NCT00426777 Phase 3 risedronate;risedronate;Control
5 The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate Completed NCT00427219 Phase 2, Phase 3 Ozarelix/Placebo;Placebo
6 Rezum FIM Optimization Unknown status NCT02940392 Not Applicable
7 Rezum I Pilot Study for BPH Unknown status NCT02943070 Not Applicable
8 Sexual Steroids: Relationship Between Serum and Prostatic Tissue Level Completed NCT02778243 Not Applicable
9 ThuLEP vs. HoLEP vs. Monopolar Enucleation in Management of BPH Completed NCT03230721 Not Applicable
10 Bone Health Observational Study Completed NCT00632905
11 Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique Recruiting NCT02940977
12 Evaluation of the Satisfaction of the Patients Operated for a Mild Hyperplasie of the Prostate by Laser in Ambulatory Surgery Recruiting NCT03474419
13 High Power Thulium Vaporization vs Transurethral Resection of the Prostate for Treatment of BPH Recruiting NCT03264482 Not Applicable
14 Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours Recruiting NCT02401581 Not Applicable
15 MRI Guided Transurethral HIFU for Various Prostate Diseases Recruiting NCT03350529 Not Applicable

Search NIH Clinical Center for Prostatic Adenoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: prostatic hyperplasia

Genetic Tests for Prostatic Adenoma

Anatomical Context for Prostatic Adenoma

MalaCards organs/tissues related to Prostatic Adenoma:

41
Prostate, Testes, Bone, Spinal Cord, Kidney, Liver, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Prostatic Adenoma:

19
The Prostate

Publications for Prostatic Adenoma

Articles related to Prostatic Adenoma:

(show top 50) (show all 969)
# Title Authors Year
1
En Bloc Thulium Laser Enucleation of the Prostate: a step-by-step guide to improve enucleation time and efficiency for endoscopic enucleation of prostatic adenoma. ( 30452968 )
2018
2
Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia. ( 30209896 )
2018
3
Increased risk of atrial fibrillation in patients with benign prostatic hyperplasia: A population-based cohort study. ( 30144121 )
2018
4
Acute urinary retention due to benign prostatic hyperplasia associated with cystitis glandularis in a 22-year-old patient. ( 30167057 )
2018
5
Risk of incident benign prostatic hyperplasia in patients with gout: a retrospective cohort study. ( 29858589 )
2018
6
Hyperthyroidism is not a significant risk of benign prostatic hyperplasia: A nationwide population-based study. ( 30278528 )
2018
7
Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasia. ( 28414251 )
2018
8
Urinary function and quality of life after radiotherapy for prostate cancer in patients with prior history of surgical treatment for benign prostatic hyperplasia. ( 30355359 )
2018
9
Risk factors for urethral stricture and/or bladder neck contracture after monopolar transurethral resection of the prostate for benign prostatic hyperplasia. ( 30426880 )
2018
10
Two unusual reports of urogenital tuberculosis: One 'putty' kidney and another in association with benign prostatic hyperplasia. ( 30522625 )
2018
11
Diet-Induced Hyperinsulinemia as a Key Factor in the Etiology of Both Benign Prostatic Hyperplasia and Essential Hypertension? ( 30455570 )
2018
12
NAD(P)H-quinone oxidoreductase 1 silencing aggravates hormone-induced prostatic hyperplasia in mice. ( 29110315 )
2018
13
Anti-Proliferative Effects of HBX-5 on Progression of Benign Prostatic Hyperplasia. ( 30322186 )
2018
14
Corni Fructus attenuates testosterone-induced benign prostatic hyperplasia by suppressing 5α-reductase and androgen receptor expression in rats. ( 30323905 )
2018
15
Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. ( 30332601 )
2018
16
Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. ( 30344644 )
2018
17
Patient-reported Goal Achievement after Treating Male Benign Prostatic Hyperplasia with Alpha-adrenergic Antagonist: A 12-week Prospective Multicenter Study. ( 30345500 )
2018
18
Banana Flower Extract Suppresses Benign Prostatic Hyperplasia by Regulating the Inflammatory Response and Inducing G1 Cell-cycle Arrest. ( 30348691 )
2018
19
Seminal vesicle abnormalities following prostatic artery embolization for the treatment of benign prostatic hyperplasia. ( 30355294 )
2018
20
A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study). ( 30358116 )
2018
21
Extreme Price Variation for Generic Benign Prostatic Hyperplasia Medications. ( 30359708 )
2018
22
Re: Vitamin D Deficiency as a Potential Marker of Benign Prostatic Hyperplasia. ( 30360296 )
2018
23
Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: a randomized, comparative study. ( 30361957 )
2018
24
Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled study. ( 30362173 )
2018
25
Editorial Comment to Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled study. ( 30362175 )
2018
26
Serenoa repens extracts: In vitro study of the 5α-reductase activity in a co-culture model for Benign Prostatic Hyperplasia. ( 30362688 )
2018
27
The Effect of Xialiqi Capsule on Testosterone-Induced Benign Prostatic Hyperplasia in Rats. ( 30364022 )
2018
28
Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride. ( 30367429 )
2018
29
Comparison of < 100 cc prostates and > 100 cc prostates undergoing aquablation for benign prostatic hyperplasia. ( 30370457 )
2018
30
Clinical Considerations for Intravesical Prostatic Protrusion in the Evaluation and Management of Bladder Outlet Obstruction Secondary to Benign Prostatic Hyperplasia. ( 30374274 )
2018
31
Effect of Veratrum maackii on testosterone propionate-induced benign prostatic hyperplasia in rats. ( 30381617 )
2018
32
Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. ( 30382600 )
2018
33
Economic Evaluation of Combination Therapy Versus Monotherapy for Treatment of Benign Prostatic Hyperplasia in Hong Kong. ( 30386234 )
2018
34
Re: A Prospective Randomised Placebo-controlled Study of the Impact of Dutasteride/Tamsulosin Combination Therapy on Sexual Function Domains in Sexually Active Men with Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH). ( 30391083 )
2018
35
Outcome of 980 nm diode laser vaporization for benign prostatic hyperplasia: A prospective study. ( 30402572 )
2018
36
Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA. ( 30410027 )
2018
37
Re: Is Early Benign Prostatic Hyperplasia (BPH) Treatment Worthwhile? ( 30412933 )
2018
38
Re: Three-Year Outcomes of the Prospective, Randomized Controlled Rezūm System Study: Convective Radiofrequency Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. ( 30412935 )
2018
39
Cost Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience. ( 30415110 )
2018
40
The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin. ( 30415813 )
2018
41
Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia? ( 30446471 )
2018
42
Prevalence and heritability of benign prostatic hyperplasia and LUTS in men aged 40 years or older in Zhengzhou rural areas. ( 30450670 )
2018
43
Outcome after prostatic artery embolization in patients with symptomatic benign prostatic hyperplasia. ( 30450921 )
2018
44
Prostatic Artery Embolization as a New Option in the Treatment of Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia - Current Evidence. ( 30457251 )
2018
45
Effects on sexual function in Japanese patients with benign prostatic hyperplasia upon switching from combination therapy with α1 blocker and dutasteride to combination therapy with tadalafil and dutasteride. ( 30457437 )
2018
46
Catheter-associated bacterial flora in patients with benign prostatic hyperplasia: shift in antimicrobial susceptibility pattern. ( 30458721 )
2018
47
Statins are effective in the treatment of benign prostatic hyperplasia with metabolic syndrome. ( 30463466 )
2018
48
Metabolic syndrome is associated worsened erectile function in patients undergoing TURP due to benign prostatic hyperplasia. ( 30468407 )
2018
49
Differentiating Transition Zone Cancers From Benign Prostatic Hyperplasia by Histogram Analysis of Apparent Diffusion Coefficient Maps With Standard and Ultrahigh b-value Diffusion-weighted MR Imaging. ( 30475249 )
2018
50
Correction to: Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride. ( 30478758 )
2018

Variations for Prostatic Adenoma

Expression for Prostatic Adenoma

Search GEO for disease gene expression data for Prostatic Adenoma.

Pathways for Prostatic Adenoma

GO Terms for Prostatic Adenoma

Cellular components related to Prostatic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 8.62 SLC25A5 SRD5A1

Biological processes related to Prostatic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of insulin secretion GO:0050796 9.26 SLC25A5 SLC25A6
2 ATP transport GO:0015867 9.16 SLC25A5 SLC25A6
3 ADP transport GO:0015866 8.96 SLC25A5 SLC25A6
4 adenine transport GO:0015853 8.62 SLC25A5 SLC25A6

Molecular functions related to Prostatic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transporter activity GO:0022857 9.16 SLC25A5 SLC25A6
2 ATP:ADP antiporter activity GO:0005471 8.96 SLC25A5 SLC25A6
3 adenine transmembrane transporter activity GO:0015207 8.62 SLC25A5 SLC25A6

Sources for Prostatic Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....